Revenue grew from $89.8M in 2024Q2 to $235.0M in 2026Q3 while gross margin expanded from 74.2% to 87.0%, though operating margin of 21.4% follows a $-6.1M operating loss in 2025Q3 and the 2025Q1 net income of $121.3M far exceeded $13.1M of operating income, warranting investigation of non-operating items.
Hinge Health, Inc. (HNGE) annual income statement — 3-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 |
|---|
| Sales/Revenue | 800.82M | 587.86M | 390.4M | 292.73M |
| Revenue Growth % | 49.86% | 50.58% | 33.37% | - |
| Cost of Goods Sold | 114.14M | 118.56M | 89.81M | 98.55M |
| COGS % of Revenue | - | 20.17% | 23% | 33.67% |
| Gross Profit | 686.68M | 469.3M | 300.59M | 194.18M |
| Gross Margin % | 85.75% | 79.83% | 77% | 66.33% |
| Gross Profit Growth % | - | 56.13% | 54.8% | - |
| Operating Expenses | 536.6M | 1.02B | 332.5M | 324.69M |
| OpEx % of Revenue | - | 172.77% | 85.17% | 110.92% |
| Selling, General & Admin | 401.31M | 639.41M | 227.53M | 214.63M |
| SG&A % of Revenue | - | 108.77% | 58.28% | 73.32% |
| Research & Development | 134.62M | 368.14M | 100.84M | 110.06M |
| R&D % of Revenue | - | 62.62% | 25.83% | 37.6% |
| Other Operating Expenses | 665K | 8.12M | 4.13M | 0 |
| Operating Income | 150.09M | -546.37M | -31.91M | -130.51M |
| Operating Margin % | 18.74% | -92.94% | -8.17% | -44.59% |
| Operating Income Growth % | - | -1612.23% | 75.55% | - |
| EBITDA | 155.77M | -541.24M | -25.96M | -124.89M |
| EBITDA Margin % | 19.45% | -92.07% | -6.65% | -42.66% |
| EBITDA Growth % | 128.45% | -1984.89% | 79.21% | - |
| D&A (Non-Cash Add-back) | 5.68M | 5.13M | 5.95M | 5.63M |
| EBIT | 158.68M | -541.02M | -24.43M | -130.51M |
| Net Interest Income | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | 16.22M | 19.11M | 20.65M | 21.97M |
| Pretax Income | 166.31M | -527.26M | -11.26M | -108.55M |
| Pretax Margin % | 20.77% | -89.69% | -2.88% | -37.08% |
| Income Tax | -2M | 998K | 677K | -405K |
| Effective Tax Rate % | -1.21% | -0.19% | -6.01% | 0.37% |
| Net Income | 168.31M | -528.26M | -11.93M | -108.14M |
| Net Margin % | 21.02% | -89.86% | -3.06% | -36.94% |
| Net Income Growth % | 139.23% | -4326.89% | 88.97% | - |
| Net Income (Continuing) | 168.31M | -528.26M | -11.93M | -108.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.95 | -5.19 | -0.15 | -1.39 |
| EPS Growth % | 135.8% | -3360% | 89.21% | - |
| EPS (Basic) | - | -5.36 | -0.15 | -1.39 |
| Diluted Shares Outstanding | 86.53M | 81.7M | 78.02M | 78.02M |
| Basic Shares Outstanding | 80.87M | 79.19M | 78.02M | 78.02M |
| Dividend Payout Ratio | - | - | - | - |
Quick answers to the most common questions about buying HNGE stock.
For fiscal year 2025, Hinge Health, Inc. (HNGE) reported total revenue of $587.9M. This represents a 100.8% increase compared to $292.7M in 2023.
Hinge Health, Inc. (HNGE) reported a net loss of $528.3M for the fiscal year ending 2025.
Hinge Health, Inc. (HNGE) reported an operating income of $-546.4M, resulting in an operating profit margin of -92.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Hinge Health, Inc. (HNGE) generated $469.3M in gross profit for the year, representing a gross profit margin of 79.8%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Operating margin not yet positive
Metrics are mathematically derived from official filings.
Sustained Top-Line Momentum Across Quarters
Based on reported figures, HNGE's revenue reached $235.0M in 2026Q3, up 52.4% year over year, suggesting growth has held near 50% for several consecutive quarters and remains durable at scale.
Quarterly revenue has compounded from $89.8M in 2024Q2 to $235.0M in 2026Q3, with year-over-year growth staying in a 45% to 55% band. This consistency suggests enterprise contract wins are converting into recognized revenue rather than reflecting a one-time step-up. Investors should monitor whether growth decelerates as the addressable employer base becomes more penetrated.
Gross Margin Expansion Supports Scalable Model
As reported in financial statements, HNGE's gross margin improved from 74.2% in 2024Q2 to 87.0% in 2026Q3, indicating that delivery costs are growing more slowly than subscription revenue.
The gross margin trajectory suggests the software and platform components are gaining weight in the revenue mix relative to clinical delivery costs. Whether this reflects AI-driven automation or favorable contract pricing cannot be determined from the reported figures alone. The margin level is strong by sector standards, though it must be weighed against the clinical labor embedded in cost of revenue.
Operating Leverage Emerging but Incomplete
Based on reported figures, HNGE's operating income swung from a $-6.1M loss in 2025Q3 to $50.3M in 2026Q3, with operating margin reaching 21.4%, indicating meaningful but uneven leverage.
SG&A has grown in absolute terms, rising to $116.5M in 2026Q3, yet operating income has expanded faster than revenue in recent quarters, which points to improving overhead absorption. The earlier 2025Q2 period, marked by a large $280.0M R&D charge, distorts the trend and should be treated as an outlier. Sustained leverage will depend on SG&A growth remaining below revenue growth.
Net Income Inflated by Non-Operating Items
According to recent SEC filings, HNGE's 2025Q1 net income of $121.3M far exceeded its $13.1M operating income, suggesting a material non-operating gain that warrants further investigation.
The gap between operating and net income in 2025Q1 implies non-operating or tax-related items that are not part of core business performance. Stock-based compensation, which reached $591.0M in 2025Q2 alongside a large R&D charge, appears to be a significant factor in reported earnings. Investors should separate recurring operating profit from these irregular items before extrapolating earnings trends.
Margin Gains Could Stall Under Platform Competition
Based on reported figures, HNGE's 52.4% revenue growth and 87.0% gross margin may not persist if large insurers bundle lower-cost digital physical therapy, a risk the recent quarters do not resolve.
The strongest bear case is that the recent margin expansion reflects favorable contract timing or capitalization choices rather than durable unit economics, which the reported figures alone cannot confirm. Operating margin of 21.4% in 2026Q3 follows a loss in 2025Q3, so a single quarter of profitability may not establish a trend. Investors should monitor whether SG&A growth stays below revenue growth and whether gross margin holds as enrollment scales.